Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Jordan SC"" wg kryterium: Autor


Tytuł :
Center-level Variation in HLA-incompatible Living Donor Kidney Transplantation Outcomes.
Autorzy :
Jackson KR; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Long J; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Motter J; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Bowring MG; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Chen J; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Waldram MM; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Orandi BJ; Department of Surgery, University of Alabama, Birmingham, AL.
Montgomery RA; The NYU Transplant Institute, New York University Langone Medical Center, New York, NY.
Stegall MD; Department of Surgery, Mayo Clinic, Rochester, MN.
Jordan SC; Department of Medicine, Cedars-Sinai Comprehensive Transplant Center, Los Angeles, CA.
Benedetti E; Department of Surgery, University of Illinois-Chicago, Chicago, IL.
Dunn TB; Department of Surgery, University of Pennsylvania, Philadelphia, PA.
Ratner LE; Department of Surgery, Columbia University Medical Center, New York, NY.
Kapur S; Department of Surgery, New York Presbyterian/Weill Cornell Medical Center, New York, NY.
Pelletier RP; Department of Surgery, Robert Wood Johnson University Hospital, New Brunswick, NJ.
Roberts JP; Department of Surgery, University of California-San Francisco, San Francisco, CA.
Melcher ML; Department of Surgery, Stanford University, Palo Alto, CA.
Singh P; Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA.
Sudan DL; Department of Surgery, Duke University Medical Center, Durham, NC.
Posner MP; Department of Surgery, Virginia Commonwealth University, Richmond, VA.
El-Amm JM; Integris Baptist Medical Center, Transplant Division, Oklahoma City, OK.
Shapiro R; Recanti Miller Transplantation Institute, Mount Sinai Hospital, New York, NY.
Cooper M; Medstar Georgetown Transplant Institute, Washington, DC.
Verbesey JE; Medstar Georgetown Transplant Institute, Washington, DC.
Lipkowitz GS; Department of Surgery, Baystate Medical Center Springfield, MA.
Rees MA; Department of Urology, University of Toledo Medical Center, Toledo, OH.
Marsh CL; Department of Surgery, Scripps Clinic and Green Hospital, La Jolla, CA.
Sankari BR; Department of Urology, Cleveland Clinic, Cleveland, OH.
Gerber DA; Department of Surgery, University of North Carolina School of Medicine, Chapel Hill, NC.
Wellen J; Department of Surgery, Barnes-Jewish Hospital, St. Louis, MO.
Bozorgzadeh A; Department of Surgery, University of Massachusetts Memorial Medical Center, Worcester, MA.
Gaber AO; Department of Surgery, Houston Methodist Hospital, Houston, TX.
Heher E; Department of Medicine, Massachusetts General Hospital, Boston, MA.
Weng FL; Renal and Pancreas Transplant Division, Saint Barnabas Medical Center, Livingston, NJ.
Djamali A; Department of Medicine, University of Wisconsin, Madison, WI.
Helderman JH; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Concepcion BP; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Brayman KL; Department of Surgery, University of Virginia, Charlottesville, VA.
Oberholzer J; Department of Surgery, University of Virginia, Charlottesville, VA.
Kozlowski T; Department of Surgery, University of Florida, Gainesville, FL.
Covarrubias K; Department of Surgery, University of California San Diego, San Diego, CA.
Desai N; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Massie AB; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Segev DL; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.; Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD.; Scientific Registry of Transplant Recipients, Minneapolis, MN.
Garonzik-Wang J; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Pokaż więcej
Źródło :
Transplantation [Transplantation] 2021 Feb 01; Vol. 105 (2), pp. 436-442.
Typ publikacji :
Journal Article; Multicenter Study; Observational Study
MeSH Terms :
Healthcare Disparities*
Histocompatibility*
Kidney Transplantation*/adverse effects
Kidney Transplantation*/mortality
Living Donors*
Practice Patterns, Physicians'*
Graft Rejection/*prevention & control
Graft Survival/*drug effects
HLA Antigens/*immunology
Immunosuppressive Agents/*therapeutic use
Isoantibodies/*blood
Adult ; Female ; Graft Rejection/blood ; Graft Rejection/immunology ; Graft Rejection/mortality ; Humans ; Immunosuppressive Agents/adverse effects ; Male ; Middle Aged ; Quality Indicators, Health Care ; Registries ; Risk Assessment ; Risk Factors ; Time Factors ; Treatment Outcome ; United States
Czasopismo naukowe
Tytuł :
Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection.
Autorzy :
Shin BH; Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA.
Everly MJ; Terasaki Research Institute, Los Angeles, CA.
Zhang H; Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA.
Choi J; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Vo A; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Zhang X; HLA and Immunogenetics Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA.
Huang E; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Jordan SC; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Toyoda M; Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA.
Pokaż więcej
Źródło :
Transplantation [Transplantation] 2020 Apr; Vol. 104 (4), pp. 856-863.
Typ publikacji :
Journal Article
MeSH Terms :
Histocompatibility*
Antibodies, Monoclonal, Humanized/*therapeutic use
Graft Rejection/*drug therapy
Graft Survival/*drug effects
HLA Antigens/*immunology
Immunoglobulins/*blood
Immunosuppressive Agents/*therapeutic use
Isoantibodies/*blood
Kidney Transplantation/*adverse effects
Adult ; Antibodies, Monoclonal, Humanized/adverse effects ; B-Lymphocytes/drug effects ; B-Lymphocytes/immunology ; Chronic Disease ; Female ; Graft Rejection/diagnosis ; Graft Rejection/immunology ; Humans ; Immunosuppressive Agents/adverse effects ; Male ; Middle Aged ; Plasma Cells/drug effects ; Plasma Cells/immunology ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation.
Autorzy :
Vo AA; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Aubert O; Paris Translational Research Center for Organ Transplantation, INSERM U970, Biostatistics Department, Paris, France.
Haas M; Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA.
Huang E; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Zhang X; Department of HLA and Immunogenetics Lab, Cedars-Sinai Medical Center, Los Angeles, CA.
Choi J; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Peng A; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Najjar R; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Sethi S; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Ammerman N; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Lim K; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Jordan SC; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Pokaż więcej
Źródło :
Transplantation [Transplantation] 2019 Dec; Vol. 103 (12), pp. 2666-2674.
Typ publikacji :
Journal Article
MeSH Terms :
Kidney Transplantation*
Tissue Donors*
Transplant Recipients*
Desensitization, Immunologic/*methods
Graft Rejection/*immunology
HLA Antigens/*immunology
Biopsy ; Female ; Graft Rejection/diagnosis ; Graft Rejection/therapy ; Graft Survival ; Histocompatibility Testing ; Humans ; Immunohistochemistry ; Immunosuppressive Agents/therapeutic use ; Isoantibodies/immunology ; Kidney/pathology ; Male ; Middle Aged ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Novel Therapeutic Approaches to Allosensitization and Antibody-mediated Rejection.
Autorzy :
Jordan SC; Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA.
Ammerman N; Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA.
Choi J; Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA.
Huang E; Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA.
Peng A; Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA.
Sethi S; Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA.
Najjar R; Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA.
Toyoda M; Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA.
Lim K; Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA.
Louie S; Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA.
Vo A; Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA.
Pokaż więcej
Źródło :
Transplantation [Transplantation] 2019 Feb; Vol. 103 (2), pp. 262-272.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Graft Rejection/*drug therapy
HLA Antigens/*immunology
Isoantibodies/*immunology
Abatacept/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Desensitization, Immunologic ; Graft Rejection/etiology ; Humans ; Rituximab/therapeutic use
Czasopismo naukowe
Tytuł :
Prognostic tools to assess candidacy for and efficacy of antibody-removal therapy.
Autorzy :
Pinelli DF; Division of Transplant Surgery, Northwestern University Feinberg School of Medicine, Comprehensive Transplant Center, Chicago, IL, USA.
Zachary AA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Friedewald JJ; Division of Nephrology and Hypertension, Department of Medicine, Northwestern University, Chicago, IL, USA.
Gjertson DW; Division of Biostatistics, University of California, Los Angeles School of Public Health, Los Angeles, CA, USA.
Evans MA; Division of Transplant Surgery, Northwestern University Feinberg School of Medicine, Comprehensive Transplant Center, Chicago, IL, USA.
Chatroop EN; Division of Transplant Surgery, Northwestern University Feinberg School of Medicine, Comprehensive Transplant Center, Chicago, IL, USA.
Leffell MS; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Vo AA; Cedars-Sinai Medical Center, Comprehensive Transplant Center, Los Angeles, CA, USA.
Jordan SC; Cedars-Sinai Medical Center, Comprehensive Transplant Center, Los Angeles, CA, USA.
Montgomery RA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Tambur AR; Division of Transplant Surgery, Northwestern University Feinberg School of Medicine, Comprehensive Transplant Center, Chicago, IL, USA.
Pokaż więcej
Źródło :
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2019 Feb; Vol. 19 (2), pp. 381-390. Date of Electronic Publication: 2018 Aug 23.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Kidney Transplantation*
Desensitization, Immunologic/*methods
Graft Rejection/*prevention & control
HLA Antigens/*immunology
Immunoglobulins, Intravenous/*administration & dosage
Isoantibodies/*blood
Plasmapheresis/*methods
Adult ; Aged ; Female ; Follow-Up Studies ; Glomerular Filtration Rate ; Graft Rejection/immunology ; Graft Survival/immunology ; Histocompatibility ; Humans ; Kidney Failure, Chronic/surgery ; Kidney Function Tests ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Hospital readmissions following HLA-incompatible live donor kidney transplantation: A multi-center study.
Autorzy :
Orandi BJ; Department of Surgery, University of California-San Francisco, San Francisco, CA, USA.
Luo X; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
King EA; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Garonzik-Wang JM; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Bae S; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Montgomery RA; The NYU Transplant Institute, New York University Langone Medical Center, New York , NY, USA.
Stegall MD; Department of Surgery, Mayo Clinic, Rochester, MN, USA.
Jordan SC; Department of Medicine, Cedars-Sinai Comprehensive Transplant Center, Los Angeles, CA, USA.
Oberholzer J; Department of Surgery, University of Illinois-Chicago, Chicago, IL, USA.
Dunn TB; Department of Surgery, University of Minnesota, Minneapolis, MN, USA.
Ratner LE; Department of Surgery, Columbia University Medical Center, New York, NY, USA.
Kapur S; Department of Surgery, New York Presbyterian/Weill Cornell Medical Center, New York, NY, USA.
Pelletier RP; Department of Surgery, The Ohio State University, Columbus, OH, USA.
Roberts JP; Department of Surgery, University of California-San Francisco, San Francisco, CA, USA.
Melcher ML; Department of Surgery, Stanford University, Palo Alto, CA, USA.
Singh P; Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Sudan DL; Department of Surgery, Duke University Medical Center, Durham, NC, USA.
Posner MP; Department of Surgery, Virginia Commonwealth University, Richmond, VA, USA.
El-Amm JM; Integris Baptist Medical Center, Transplant Division, Oklahoma City, OK, USA.
Shapiro R; Recanati Miller Transplantation Institute, Mount Sinai Hospital, New York, NY, USA.
Cooper M; Medstar Georgetown Transplant Institute, Washington, DC, USA.
Lipkowitz GS; Department of Surgery, Baystate Medical Center, Springfield, MA, USA.
Rees MA; Department of Urology, University of Toledo Medical Center, Toledo, OH, USA.
Marsh CL; Department of Surgery, Scripps Clinic and Green Hospital, La Jolla, CA, USA.
Sankari BR; Department of Urology, Cleveland Clinic, Cleveland, OH, USA.
Gerber DA; Department of Surgery, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Nelson PW; Department of Surgery, University of Nevada, Las Vegas, NV, USA.
Wellen J; Department of Surgery, Barnes-Jewish Hospital, St. Louis, MO, USA.
Bozorgzadeh A; Department of Surgery, University of Massachusetts Memorial Medical Center, Worcester, MA, USA.
Osama Gaber A; Department of Surgery, Houston Methodist Hospital, Houston, TX, USA.
Segev DL; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Pokaż więcej
Źródło :
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2018 Mar; Vol. 18 (3), pp. 650-658. Date of Electronic Publication: 2017 Sep 23.
Typ publikacji :
Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
MeSH Terms :
Postoperative Complications*
Blood Group Incompatibility/*immunology
HLA Antigens/*immunology
Kidney Failure, Chronic/*surgery
Kidney Transplantation/*methods
Living Donors/*supply & distribution
Patient Readmission/*statistics & numerical data
Adult ; Case-Control Studies ; Female ; Follow-Up Studies ; Glomerular Filtration Rate ; Graft Survival ; Hospitalization/statistics & numerical data ; Humans ; Isoantibodies/blood ; Isoantibodies/immunology ; Kidney Function Tests ; Male ; Middle Aged ; Prognosis ; Risk Factors
Czasopismo naukowe
Tytuł :
Risk factors for the development of antibody-mediated rejection in highly sensitized pediatric kidney transplant recipients.
Autorzy :
Kim IK; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Choi J; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Vo A; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Kang A; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Steggerda J; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Louie S; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Haas M; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Mirocha J; Biostatistics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Cohen JL; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Pizzo H; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Kamil ES; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Jordan SC; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Puliyanda D; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Pokaż więcej
Źródło :
Pediatric transplantation [Pediatr Transplant] 2017 Dec; Vol. 21 (8). Date of Electronic Publication: 2017 Sep 19.
Typ publikacji :
Journal Article
MeSH Terms :
Kidney Transplantation*
Graft Rejection/*immunology
HLA Antigens/*immunology
Isoantibodies/*immunology
Adolescent ; Child ; Child, Preschool ; Desensitization, Immunologic/methods ; Female ; Graft Rejection/prevention & control ; Graft Survival/immunology ; Humans ; Immunosuppressive Agents/therapeutic use ; Kaplan-Meier Estimate ; Male ; Retrospective Studies ; Risk Factors ; Transplantation, Homologous ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Plasma Exosomes From HLA-Sensitized Kidney Transplant Recipients Contain mRNA Transcripts Which Predict Development of Antibody-Mediated Rejection.
Autorzy :
Zhang H; 1 Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA. 2 Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA. 3 Department of Nephrology, Kaiser-Permanente Los Angeles Medical Center, Los Angeles, CA. 4 Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA. 5 Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA. 6 Biostatistics and Bioinformatics Research Center, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
Huang E
Kahwaji J
Nast CC
Li P
Mirocha J
Thomas DL
Ge S
Vo AA
Jordan SC
Toyoda M
Pokaż więcej
Źródło :
Transplantation [Transplantation] 2017 Oct; Vol. 101 (10), pp. 2419-2428.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Histocompatibility*
Exosomes/*metabolism
Graft Rejection/*blood
HLA Antigens/*immunology
Isoantibodies/*blood
Kidney Transplantation/*adverse effects
RNA, Messenger/*blood
Adult ; Case-Control Studies ; Chemokine CCL4/genetics ; Cytokine Receptor gp130/genetics ; Exosomes/genetics ; Female ; Gene Expression Profiling/methods ; Genetic Markers ; Graft Rejection/genetics ; Graft Rejection/immunology ; Humans ; Male ; Middle Aged ; Predictive Value of Tests ; RNA, Messenger/genetics ; Real-Time Polymerase Chain Reaction ; Reverse Transcriptase Polymerase Chain Reaction ; Risk Assessment ; Risk Factors ; Transcription Factors/genetics ; Treatment Outcome ; Tumor Necrosis Factor-alpha/genetics
Czasopismo naukowe
Tytuł :
Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
Autorzy :
Choi J; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Aubert O; Paris Translational Research Center for Organ Transplantation, INSERM U970, Biostatistics Department, Paris, France.
Vo A; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Loupy A; Paris Translational Research Center for Organ Transplantation, INSERM U970, Biostatistics Department, Paris, France.
Haas M; Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA.
Puliyanda D; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Kim I; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Louie S; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Kang A; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Peng A; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Kahwaji J; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Reinsmoen N; Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA.
Toyoda M; HLA Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA.
Jordan SC; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Pokaż więcej
Źródło :
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2017 Sep; Vol. 17 (9), pp. 2381-2389. Date of Electronic Publication: 2017 Mar 10.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Graft Rejection/*drug therapy
HLA Antigens/*immunology
Isoantibodies/*adverse effects
Kidney Failure, Chronic/*surgery
Kidney Transplantation/*adverse effects
Receptors, Interleukin-6/*antagonists & inhibitors
Female ; Follow-Up Studies ; Glomerular Filtration Rate ; Graft Rejection/etiology ; Graft Survival/drug effects ; Graft Survival/immunology ; Humans ; Immunosuppressive Agents/therapeutic use ; Kidney Function Tests ; Male ; Middle Aged ; Prognosis ; Receptors, Interleukin-6/immunology ; Risk Factors ; Transplantation, Homologous
Czasopismo naukowe
Tytuł :
IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation.
Autorzy :
Jordan SC; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Lorant T; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Choi J; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Kjellman C; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Winstedt L; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Bengtsson M; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Zhang X; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Eich T; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Toyoda M; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Eriksson BM; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Ge S; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Peng A; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Järnum S; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Wood KJ; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Lundgren T; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Wennberg L; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Bäckman L; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Larsson E; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Villicana R; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Kahwaji J; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Louie S; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Kang A; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Haas M; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Nast C; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Vo A; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Tufveson G; From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2017 Aug 03; Vol. 377 (5), pp. 442-453.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Kidney Transplantation*
Transplantation Immunology*
Bacterial Proteins/*therapeutic use
Cysteine Endopeptidases/*therapeutic use
HLA Antigens/*immunology
Immunosuppression/*methods
Adult ; Antibodies/blood ; Bacterial Proteins/adverse effects ; Complement C1q/immunology ; Cysteine Endopeptidases/adverse effects ; Female ; Histocompatibility Testing ; Humans ; Immunoglobulin G/blood ; Immunoglobulin G/metabolism ; Male ; Middle Aged
Czasopismo naukowe
Tytuł :
Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant Recipients.
Autorzy :
Kim IK; 1 Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA. 2 Biostatistics Core, Cedars-Sinai Medical Center, Los Angeles, CA.
Choi J
Vo AA
Kang A
Patel M
Toyoda M
Mirocha J
Kamil ES
Cohen JL
Louie S
Galera O
Jordan SC
Puliyanda DP
Pokaż więcej
Źródło :
Transplantation [Transplantation] 2017 Apr; Vol. 101 (4), pp. 883-889.
Typ publikacji :
Journal Article
MeSH Terms :
Histocompatibility*
Antibodies, Monoclonal, Humanized/*therapeutic use
Desensitization, Immunologic/*methods
Graft Rejection/*prevention & control
Graft Survival/*drug effects
HLA Antigens/*immunology
Immunosuppressive Agents/*therapeutic use
Kidney Transplantation/*adverse effects
Lymphocyte Depletion/*methods
Adolescent ; Age Factors ; Alemtuzumab ; Antibodies, Monoclonal, Humanized/adverse effects ; Biomarkers/blood ; Child ; Desensitization, Immunologic/adverse effects ; Drug Therapy, Combination ; Female ; Graft Rejection/immunology ; Graft Rejection/mortality ; Humans ; Immunocompromised Host ; Immunoglobulins, Intravenous/therapeutic use ; Immunosuppressive Agents/adverse effects ; Isoantibodies/blood ; Kaplan-Meier Estimate ; Kidney Transplantation/mortality ; Lymphocyte Count ; Lymphocyte Depletion/adverse effects ; Male ; Opportunistic Infections/immunology ; Opportunistic Infections/virology ; Retrospective Studies ; Risk Factors ; Rituximab/therapeutic use ; Time Factors ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.
Autorzy :
Haas M; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA. Electronic address: .
Mirocha J; Biostatistics Core, Research Institute and General Clinical Research Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Reinsmoen NL; HLA and Immunogenetics Laboratory, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Vo AA; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Choi J; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Kahwaji JM; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Peng A; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Villicana R; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA; Transplantation Institute, Loma Linda University Medical Center, Loma Linda, California, USA.
Jordan SC; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Pokaż więcej
Źródło :
Kidney international [Kidney Int] 2017 Mar; Vol. 91 (3), pp. 729-737. Date of Electronic Publication: 2017 Jan 16.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Graft Survival*/drug effects
Graft Rejection/*diagnosis
HLA Antigens/*immunology
Isoantibodies/*blood
Kidney/*immunology
Kidney/*pathology
Kidney Transplantation/*adverse effects
Adult ; Allografts ; Atrophy ; Biopsy ; Complement C4b/analysis ; Female ; Fibrosis ; Graft Rejection/drug therapy ; Graft Rejection/immunology ; Graft Rejection/pathology ; Histocompatibility ; Humans ; Immunosuppressive Agents/therapeutic use ; Kaplan-Meier Estimate ; Kidney/drug effects ; Los Angeles ; Male ; Middle Aged ; Peptide Fragments/analysis ; Predictive Value of Tests ; Proportional Hazards Models ; Retrospective Studies ; Risk Factors ; Serologic Tests ; Time Factors
Czasopismo naukowe
Tytuł :
Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients.
Autorzy :
Toyoda M; Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Shin BH; Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Ge S; Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Mirocha J; Biostatistics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Thomas D; Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Chu M; Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Rodriguez E; Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Chao C; Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Petrosyan A; Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Galera OA; Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Vo A; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Choi J; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Peng A; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Kahwaji J; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Jordan SC; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Pokaż więcej
Źródło :
Journal of immunology research [J Immunol Res] 2017; Vol. 2017, pp. 5672523. Date of Electronic Publication: 2017 Feb 06.
Typ publikacji :
Journal Article
MeSH Terms :
Desensitization, Immunologic*
Kidney Transplantation*
Cytomegalovirus Infections/*immunology
Epstein-Barr Virus Infections/*immunology
HLA Antigens/*immunology
Adult ; Aged ; Alemtuzumab ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal, Murine-Derived/therapeutic use ; Antiviral Agents/therapeutic use ; BK Virus ; Cytomegalovirus Infections/drug therapy ; Cytomegalovirus Infections/prevention & control ; Cytomegalovirus Infections/virology ; Epstein-Barr Virus Infections/drug therapy ; Epstein-Barr Virus Infections/prevention & control ; Epstein-Barr Virus Infections/virology ; Female ; Humans ; Immunoglobulins, Intravenous/therapeutic use ; Kidney/immunology ; Lymphocyte Depletion ; Male ; Middle Aged ; Polyomavirus Infections/drug therapy ; Polyomavirus Infections/immunology ; Polyomavirus Infections/virology ; Rituximab/therapeutic use ; Transplant Recipients ; Transplantation, Homologous ; Viremia/drug therapy ; Viremia/immunology ; Viremia/prevention & control
Czasopismo naukowe
Tytuł :
Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.
Autorzy :
Kahwaji J; Cedars-Sinai Medical Center, Comprehensive Transplant Center, Los Angeles, CA, USA.
Jordan SC; Cedars-Sinai Medical Center, Comprehensive Transplant Center, Los Angeles, CA, USA.
Najjar R; Cedars-Sinai Medical Center, Comprehensive Transplant Center, Los Angeles, CA, USA.
Wongsaroj P; Cedars-Sinai Medical Center, Comprehensive Transplant Center, Los Angeles, CA, USA.
Choi J; Cedars-Sinai Medical Center, Comprehensive Transplant Center, Los Angeles, CA, USA.
Peng A; Cedars-Sinai Medical Center, Comprehensive Transplant Center, Los Angeles, CA, USA.
Villicana R; Cedars-Sinai Medical Center, Comprehensive Transplant Center, Los Angeles, CA, USA.
Vo A; Cedars-Sinai Medical Center, Comprehensive Transplant Center, Los Angeles, CA, USA.
Pokaż więcej
Źródło :
Transplant international : official journal of the European Society for Organ Transplantation [Transpl Int] 2016 Dec; Vol. 29 (12), pp. 1276-1285. Date of Electronic Publication: 2016 Oct 24.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Desensitization, Immunologic*
HLA Antigens/*immunology
Immunoglobulins, Intravenous/*therapeutic use
Kidney Failure, Chronic/*surgery
Kidney Transplantation/*methods
Rituximab/*therapeutic use
Adult ; Female ; Follow-Up Studies ; Glomerular Filtration Rate ; Graft Rejection ; Graft Survival ; Histocompatibility Testing ; Humans ; Immunosuppression ; Immunosuppressive Agents/therapeutic use ; Kidney Failure, Chronic/mortality ; Living Donors ; Male ; Middle Aged ; Proteinuria/immunology ; Retrospective Studies ; Risk Factors ; Transplant Recipients ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Risk factors associated with the development of histocompatibility leukocyte antigen sensitization.
Autorzy :
Jordan SC; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Choi J
Kim I
Vo A
Peng A
Kahwaji J
Pokaż więcej
Źródło :
Current opinion in organ transplantation [Curr Opin Organ Transplant] 2016 Aug; Vol. 21 (4), pp. 447-52.
Typ publikacji :
Journal Article; Review
MeSH Terms :
HLA Antigens/*immunology
Histocompatibility Testing/*methods
Transplantation, Homologous/*methods
Graft Rejection/immunology ; Humans ; Risk Factors
Czasopismo naukowe
Tytuł :
Progress in Desensitization of the Highly HLA Sensitized Patient.
Autorzy :
Jordan SC; Transplant Immunotherapy Program, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California. Electronic address: stan.jordan@cshs.org.
Choi J; Transplant Immunotherapy Program, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California.
Kahwaji J; Transplant Immunotherapy Program, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California.
Vo A; Transplant Immunotherapy Program, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California.
Pokaż więcej
Źródło :
Transplantation proceedings [Transplant Proc] 2016 Apr; Vol. 48 (3), pp. 802-5.
Typ publikacji :
Journal Article
MeSH Terms :
Desensitization, Immunologic/*methods
Graft Rejection/*immunology
HLA Antigens/*immunology
Humans ; Immunoglobulins, Intravenous/therapeutic use ; Kidney Transplantation ; Plasma Exchange ; Rituximab/therapeutic use
Czasopismo naukowe
Tytuł :
Donor-Specific HLA Antibody IgG Subclasses Are Associated with Phenotypes of Antibody-Mediated Rejection in Sensitized Renal Allograft Recipients.
Autorzy :
Jordan SC; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California .
Pokaż więcej
Źródło :
Journal of the American Society of Nephrology : JASN [J Am Soc Nephrol] 2016 Jan; Vol. 27 (1), pp. 6-8. Date of Electronic Publication: 2015 Aug 20.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Antibody Specificity*
Kidney Transplantation*
Transplantation Immunology*
Allografts/*immunology
HLA Antigens/*immunology
Immunoglobulin G/*classification
Immunoglobulin G/*immunology
Kidney Diseases/*immunology
Postoperative Complications/*immunology
Female ; Humans ; Male
Opinia redakcyjna
Tytuł :
Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
Autorzy :
Vo AA; 1 Kidney Transplant Program and Transplant Immunology, Cedars-Sinai Medical Center, Los Angeles, CA. 2 Division of Pediatric Nephrology, All India Institute of Medical Sciences, New Delhi, India. 3 Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA. 4 Biostatistics Core, Cedars-Sinai Medical Center, Los Angeles, CA.
Sinha A
Haas M
Choi J
Mirocha J
Kahwaji J
Peng A
Villicana R
Jordan SC
Pokaż więcej
Źródło :
Transplantation [Transplantation] 2015 Jul; Vol. 99 (7), pp. 1423-30.
Typ publikacji :
Journal Article
MeSH Terms :
Histocompatibility*
Desensitization, Immunologic/*methods
Graft Rejection/*prevention & control
Graft Survival/*drug effects
HLA Antigens/*immunology
Immunity, Humoral/*drug effects
Immunosuppressive Agents/*administration & dosage
Isoantibodies/*blood
Kidney Transplantation/*methods
Adult ; Biomarkers/blood ; Desensitization, Immunologic/adverse effects ; Desensitization, Immunologic/mortality ; Female ; Graft Rejection/blood ; Graft Rejection/immunology ; Graft Rejection/mortality ; Histocompatibility Testing ; Humans ; Immunoglobulins, Intravenous/administration & dosage ; Immunosuppressive Agents/adverse effects ; Kaplan-Meier Estimate ; Kidney Transplantation/adverse effects ; Kidney Transplantation/mortality ; Male ; Middle Aged ; Predictive Value of Tests ; Retrospective Studies ; Risk Factors ; Rituximab/administration & dosage ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients.
Autorzy :
Vo AA; 1 Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA. 2 Immunogenetics Laboratory, University of Pittsburgh Medical Center, Pittsburgh, PA. 3 Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA. 4 HLA & Immunogenetics Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA. 5 Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA.
Zeevi A
Choi J
Cisneros K
Toyoda M
Kahwaji J
Peng A
Villicana R
Puliyanda D
Reinsmoen N
Haas M
Jordan SC
Pokaż więcej
Źródło :
Transplantation [Transplantation] 2015 Feb; Vol. 99 (2), pp. 299-308.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Histocompatibility*
Complement Activation/*drug effects
Complement C1 Inhibitor Protein/*therapeutic use
Graft Rejection/*prevention & control
Graft Survival/*drug effects
HLA Antigens/*immunology
Immunosuppressive Agents/*therapeutic use
Isoantibodies/*blood
Kidney Failure, Chronic/*surgery
Kidney Transplantation/*adverse effects
Adult ; Biomarkers/blood ; Complement C1 Inhibitor Protein/adverse effects ; Complement C1q/immunology ; Double-Blind Method ; Female ; Graft Rejection/immunology ; Humans ; Immunosuppressive Agents/adverse effects ; Kidney Failure, Chronic/blood ; Kidney Failure, Chronic/diagnosis ; Kidney Failure, Chronic/immunology ; Los Angeles ; Male ; Middle Aged ; Plasma Exchange ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Quantifying the risk of incompatible kidney transplantation: a multicenter study.
Autorzy :
Orandi BJ; Departments of Surgery and Medicine, Johns Hopkins Hospital, Baltimore, MD.
Garonzik-Wang JM
Massie AB
Zachary AA
Montgomery JR
Van Arendonk KJ
Stegall MD
Jordan SC
Oberholzer J
Dunn TB
Ratner LE
Kapur S
Pelletier RP
Roberts JP
Melcher ML
Singh P
Sudan DL
Posner MP
El-Amm JM
Shapiro R
Cooper M
Lipkowitz GS
Rees MA
Marsh CL
Sankari BR
Gerber DA
Nelson PW
Wellen J
Bozorgzadeh A
Gaber AO
Montgomery RA
Segev DL
Pokaż więcej
Źródło :
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2014 Jul; Vol. 14 (7), pp. 1573-80. Date of Electronic Publication: 2014 Jun 09.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
MeSH Terms :
Antibodies/*immunology
Blood Group Incompatibility/*epidemiology
Graft Rejection/*etiology
HLA Antigens/*immunology
Kidney Transplantation/*legislation & jurisprudence
Kidney Transplantation/*statistics & numerical data
Living Donors/*supply & distribution
Adult ; Blood Group Incompatibility/diagnosis ; Blood Group Incompatibility/immunology ; Female ; Follow-Up Studies ; Graft Survival ; Humans ; Incidence ; Kidney Failure, Chronic/mortality ; Kidney Failure, Chronic/surgery ; Male ; Middle Aged ; Postoperative Complications/mortality ; Practice Patterns, Physicians'/statistics & numerical data ; Prognosis ; Risk Factors ; Survival Rate
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies